A Phase 2 Multicenter Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment (CodeBreaK 201) | NYU Langone Health

Go Back to All Clinical Trials

A Phase 2 Multicenter Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment (CodeBreaK 201)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non-small Cell Lung Cancer (nsclc)
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic disease. 2) Ability to take oral medications and willing to record daily adherence to investigational product. 3) Adequate hematological laboratory assessments, defined as the following within 10 days prior to start of study therapy.

You may not be eligible for this study if the following are true:

1) Mixed small-cell lung cancer and NSCLC histology. 2) Subject has received prior treatment for metastatic NSCLC. 3) Subjects who receive adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic disease.